Changes in von Willebrand factor and ADAMTS13 during IVF

Area of Science:

• Reproductive Endocrinology
• Hematology
• Thrombosis Research

Background:

• Elevated estradiol during IVF can impact hemostasis.
• High von Willebrand factor (VWF) levels are a risk factor for thrombosis.
• ADAMTS13, the VWF-cleaving protease, plays a key regulatory role but its changes during IVF are unknown.

Purpose of the Study:

• To investigate the impact of IVF-induced estradiol fluctuations on VWF and ADAMTS13 levels.
• To explore the relationship between these hemostatic factors and thrombotic risk in IVF patients.

Main Methods:

• Blood samples were collected from 31 women undergoing IVF.
• Measurements included estradiol, VWF antigen and activity, factor VIII, and ADAMTS13 antigen and activity.
• Samples were taken during maximal estradiol downregulation and high estradiol stimulation phases.

Main Results:

• Estradiol levels significantly increased from 154 pg/ml to 5889 pg/ml.
• Factor VIII, VWF antigen, and VWF activity all showed significant increases (P < 0.001).
• ADAMTS13 antigen and activity significantly decreased (P < 0.05 and P < 0.01, respectively).

Conclusions:

• IVF treatment leads to increased VWF and factor VIII, alongside decreased ADAMTS13.
• These hemostatic changes during IVF may contribute to an elevated risk of thrombotic events.